SMS Pharmaceuticals Ltd
SMS Pharmaceuticals Q1 FY27: Revenue ₹207 Cr, PAT ₹20 Cr
Q1 FY27 investor presentation: what the company reported on revenue, margins and projects.
Based on SMS Pharmaceuticals Ltd's Q1 FY27 investor presentation. The company has not published an earnings-call transcript for this quarter, so figures here are what the presentation reports, not management guidance.
The short version
Q1FY27 revenue from operations: ₹207 crore, up 6% YoY (Page 6, 5) - Q1FY27 EBITDA: ₹41 crore, up 4% YoY (Page 6) - Q1FY27 PAT: ₹20 crore, up 8% YoY (Page 6) - EPS for Q1FY27: ₹2.23 (Page 6) - Revenue from operations for FY26: ₹586.87 crore, up 13% YoY from FY25 (₹782.75 crore appears to be a typo or formatting issue; likely FY25 revenue was ₹782.75 crore as a base) (Page 27) - Gross margin steady at around 34-36% in Q1FY27 (Page 27) - No explicit volume figures for the quarter provided. Quarterly (Q1FY27) figures: - EBITDA: ₹41 crore, up 4% YoY - EBITDA Margin: 20%, sustained QoQ and YoY - PAT: ₹20 crore, up 8% YoY - PAT Margin: 10%, up slightly YoY - Year-on-Year (YoY)
From SMS Pharmaceuticals Ltd's Q1 FY27 earnings-call transcript · updated 25 Sept 2026.
Revenue & Sales Performance
- Q1FY27 revenue from operations: ₹207 crore, up 6% YoY (Page 6, 5)
- Q1FY27 EBITDA: ₹41 crore, up 4% YoY (Page 6)
- Q1FY27 PAT: ₹20 crore, up 8% YoY (Page 6)
- EPS for Q1FY27: ₹2.23 (Page 6)
- Revenue from operations for FY26: ₹586.87 crore, up 13% YoY from FY25 (₹782.75 crore appears to be a typo or formatting issue; likely FY25 revenue was ₹782.75 crore as a base) (Page 27)
- Gross margin steady at around 34-36% in Q1FY27 (Page 27)
- No explicit volume figures for the quarter provided.
- Outlook mentions capex programme of ₹280 crore to be completed by FY27 to support capacity expansion and new API pipeline (Page 25)
2 more points management made on revenue & sales performance
Profitability & Margins
See what SMS Pharmaceuticals Ltd said on profitability & margins — free account, 30 seconds.
Capital Expenditure Plans
2 more points management made on capital expenditure plans
Top-ranked in Pharmaceuticals & Biotechnology
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Fundraising & Capital Structure
See what SMS Pharmaceuticals Ltd said on fundraising & capital structure — free account, 30 seconds.
Order Book & Pipeline
2 more points management made on order book & pipeline
SMS Pharmaceuticals Ltd — Quarterly revenue & net profit
Reported quarterly figures (₹ Cr). Latest: revenue ₹238 Cr, net profit ₹21 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →Continue your research
What SMS Pharmaceuticals Ltd's management said in earlier quarters
- Q3 FY26 earnings call analysis →
- Q3 FY25 earnings call analysis →
- Q1 FY26 earnings call analysis →
- Q2 FY26 earnings call analysis →
- Q4 FY25 earnings call →
- Q2 FY25 earnings call →
- Q1 FY25 earnings call →
- Q4 FY24 earnings call →
- Q3 FY24 earnings call →
- Q2 FY24 earnings call →
- Q1 FY24 earnings call →
- Q4 FY23 earnings call →
Others in Pharmaceuticals & Biotechnology this season
- Aptus Pharma Ltd (Q1 FY27)
Revenue from Operations for H2 FY26: ₹32.20 crore, up 117.5% YoY from ₹14.80 crore in H2 FY25 (Page 23) . Key concall takeaways from Aptus Pharma Ltd's Q1 FY27…
- RPG Life Sciences Ltd (Q1 FY27)
Q1 FY27 Revenue from Operations: ₹195.7 crores, up 15.8% YoY (Q1 FY26: ₹168.9 crores) [Page 18] . Key concall takeaways from RPG Life Sciences Ltd's Q1 FY27…
- Wanbury Ltd (Q1 FY27)
Q4FY26 Revenue from Operations: ₹164.58 Crore . Key concall takeaways from Wanbury Ltd's Q1 FY27 earnings call — and how it ranks against sector peers.
- Symbiotec Pharmalab Ltd (Q1 FY27)
Q1 FY27 consolidated revenue from operations: ₹218.2 crores, up 7% YoY from ₹203.2 crores in Q1 FY26 (Page 9). Key concall takeaways from Symbiotec Pharmalab…
Frequently Asked Questions
What were SMS Pharmaceuticals Ltd Q1 FY27 results?
Q1FY27 revenue from operations: ₹207 crore, up 6% YoY (Page 6, 5) - Q1FY27 EBITDA: ₹41 crore, up 4% YoY (Page 6) - Q1FY27 PAT: ₹20 crore, up 8% YoY (Page 6) - EPS for Q1FY27: ₹2.23 (Page 6) - Revenue from operations for FY26: ₹586.87 crore, up 13% YoY from FY25 (₹782.75 crore appears to be a typo or formatting issue; likely FY25 revenue was ₹782.75 crore as a base) (Page 27) - Gross margin steady at around 34-36% in Q1FY27 (Page 27) - No explicit volume figures for the quarter provided. Quarterly (Q1FY27) figures: - EBITDA: ₹41 crore, up 4% YoY - EBITDA Margin: 20%, sustained QoQ and YoY - PAT: ₹20 crore, up 8% YoY - PAT Margin: 10%, up slightly YoY - Year-on-Year (YoY)
What is SMS Pharmaceuticals Ltd share price analysis?
SMS Pharmaceuticals Ltd currently shows a neutral. The stock trades at a P/E of 40.5 with a market cap of ₹4,148 Cr. Investors should review the full earnings analysis for detailed insights.
Is SMS Pharmaceuticals Ltd planning capital expenditure?
Capex spend of ₹280 crore planned to be completed by FY27 (Page 25).
Keep SMS Pharmaceuticals Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and the company's investor presentation. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.